[Asia Economy Reporter Hyunseok Yoo] Neurophat, a specialized AI solution company for brain diseases, announced on the 7th that it has obtained the European CE certification for its brain imaging analysis software, 'Neurophat AQUA (NEUROPHET AQUA)'.
'Neurophat AQUA' is a brain disease analysis solution that segments a patient's brain magnetic resonance imaging (MRI) to produce an objective report on conditions such as the degree of brain atrophy. By applying its core AI-based technology, 'Neurophat SegEngine', to the 'Neurophat AQUA' solution, it enables MRI segmentation and analysis within one minute regardless of race, age, or gender.
With this CE certification, Neurophat can now supply 'Neurophat AQUA' to the European market. According to European market research firm Yole Development, the global medical imaging AI market has grown at an average annual rate of 36% since 2019 and is expected to exceed $2.9 billion USD (approximately 3.2625 trillion KRW) by 2025.
Bin Jungil, CEO of Neurophat, stated, "By obtaining the stringent European CE certification, we have proven AQUA's technological capabilities overseas," and added, "We will accelerate our global expansion through local testing and joint research with European medical institutions."
Meanwhile, Neurophat obtained Class 2 medical device certification from the Ministry of Food and Drug Safety in March for the upgraded version of AQUA, 'AQUA 2.0', which is scheduled to be released later this month.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
